Study of HLD-0915 in Patients With Metastatic Prostate Cancer
ConditionMetastatic Prostate Cancer
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexMale
Age18+
SponsorHalda Therapeutics OpCo, Inc.
About this trial
Assessment of the safety and efficacy of HLD-0915 in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- HLD-0915 Hard Capsule
- HLD-0915 Tablet
- HLD-0915 Soft Capsule
Treatment groups
190 Participants
are divided into 7 treatment groups7
Treatment groupsSee each treatment group below.
Locations
12United Kingdom
Royal Marsden HospitalSM2 5PT, SuttonSurrey, United Kingdom
United States
Colorado
Sarah Cannon Research Institute at HealthONE80218, Denver United States
Connecticut
Yale - New Haven Hospital - Yale Cancer Center06520, New Haven United States
Florida
Florida Cancer Specialists34232, Sarasota United States
Sponsors and collaborators
Halda Therapeutics OpCo, Inc.
Lead sponsor
Source ClinicalTrials.gov